ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Conference Call and Live Audio Webcast Scheduled for November 9th, 2016, 5:00 p.m. ET
CORALVILLE, Iowa, Nov. 01, 2016 -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Wednesday, November 9, 2016, at 5:00 p.m. ET, to discuss its corporate and financial results for the third quarter 2016.
Conference Call Information:
Interested participants and investors may access the conference call by dialing either:
- (866) 395-2480 (U.S.)
- (678) 509-7538 (international)
- Conference ID: 11692265
An audio webcast will be accessible via the Investor Relations section of the KemPharm website http://investors.kempharm.com/. An archive of the webcast will remain available for 90 days beginning at approximately 6:00 p.m. ET, on November 9, 2016.
About KemPharm
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its LAT platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, ADHD and other CNS disorders.
| Investor Contacts: | Media Contact: | |||
| Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 [email protected] [email protected] | Daniel L. Cohen Executive Vice President, Government and Public Relations KemPharm, Inc. 202-329-1825 [email protected] |
